PMID- 9566703
OWN - NLM
STAT- MEDLINE
DCOM- 19980508
LR  - 20190720
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 125
IP  - 1-2
DP  - 1998 Mar 13
TI  - Inhibitory effect of selenomethionine on the growth of three selected human tumor 
      cell lines.
PG  - 103-10
AB  - Selenium supplementation has been shown for many years to work as an 
      anticarcinogenic agent both in epidemiology and in in vitro studies. Selenium 
      supplementation has recently been shown to decrease total cancer incidence. 
      However, the mechanism of action of selenium as an anticarcinogenic agent has yet 
      to be elucidated. Selenomethionine was the predominant form of selenium in the 
      dietary supplement in the study by Clark et al. (Clark, L.C., Combs, G.F., 
      Turnbull, W.B., Slate, E.H., Chalker, D.K., Chow, J., Davis, L.S., Glover, R.A., 
      Graham, G.F., Gross, E.G., Krongrad, A., Lesher, J.L., Park, H.K., Sanders, B.B., 
      Smith, C.L., Taylor, J.R. and The Nutritional Prevention of Cancer Study Group 
      (1996) Effects of selenium supplementation for cancer prevention in patients with 
      carcinoma of the skin: a randomized controlled trial. J. Am. Med. Assoc., 276 
      (24), 1957-1963) and therefore we evaluated the growth inhibitory effects of 
      selenomethionine against human tumor cells. Selenomethionine was tested against 
      each of three human tumor cell lines (MCF-7/S breast carcinoma, DU-145 prostate 
      cancer cells and UACC-375 melanoma) and against normal human diploid fibroblasts. 
      All cell lines demonstrated a dose-dependent manner of growth inhibition by 
      selenomethionine. Selenomethionine inhibited the growth of all of the human tumor 
      cell lines in the micromolar (microM) range (ranging from 45 to 130 microM) while 
      growth inhibition of normal diploid fibroblasts required 1 mM selenomethionine, 
      approximately 1000-fold higher than for the cancer cell lines. In short, normal 
      diploid fibroblasts were less sensitive than the cancer cell lines to the growth 
      inhibitory effects of selenomethionine. Furthermore, we show that 
      selenomethionine administration to these cancer cell lines results in apoptotic 
      cell death and aberrant mitoses. These results demonstrate the differential 
      sensitivity of tumor cells and normal cells to selenomethionine.
FAU - Redman, C
AU  - Redman C
AD  - Pharmacology/Toxicology Department, The University of Arizona, Tucson 85724, USA.
FAU - Scott, J A
AU  - Scott JA
FAU - Baines, A T
AU  - Baines AT
FAU - Basye, J L
AU  - Basye JL
FAU - Clark, L C
AU  - Clark LC
FAU - Calley, C
AU  - Calley C
FAU - Roe, D
AU  - Roe D
FAU - Payne, C M
AU  - Payne CM
FAU - Nelson, M A
AU  - Nelson MA
LA  - eng
GR  - CA41108-MIS/CA/NCI NIH HHS/United States
GR  - R29 CA 70145-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antineoplastic Agents)
RN  - 964MRK2PEL (Selenomethionine)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Breast Neoplasms/pathology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Melanoma/pathology
MH  - Prostatic Neoplasms/pathology
MH  - Selenomethionine/*pharmacology
MH  - Tumor Cells, Cultured
EDAT- 1998/05/05 00:00
MHDA- 1998/05/05 00:01
CRDT- 1998/05/05 00:00
PHST- 1998/05/05 00:00 [pubmed]
PHST- 1998/05/05 00:01 [medline]
PHST- 1998/05/05 00:00 [entrez]
AID - S0304-3835(97)00497-7 [pii]
AID - 10.1016/s0304-3835(97)00497-7 [doi]
PST - ppublish
SO  - Cancer Lett. 1998 Mar 13;125(1-2):103-10. doi: 10.1016/s0304-3835(97)00497-7.